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THE serum concentration of two pro-angiogenic
cytokines: basic fibroblast growth factor (bFGF) and
transforming growth factor beta1 (TGF-b1), and anti-
angiogenic factor endostatin in the serum of 80 never
treated B-cell chronic lymphocytic leukemia (CLL)
patients and 27 healthy volunteers was measured
using an enzyme linked immunosorbent assay. The
serum levels of both bFGF and TGF-b1 were found to
be significantly higher in the CLL group (median 40.5
pg/ml and 38.6 ng/ml respectively) when compared
to the control group (median 9.4 pg/ml and 18.9 ng/
ml, respectively) (p B/0.001). The levels of endostatin
were not significantly different in CLL and control
groups (median 12.3 ng/ml and 8.4 ng/ml, respec-
tively) (p/0.09). In the group of CLL patients the
level of bFGF was significantly higher in patients with
progressive disease as compared with patients with
stable disease (median 90.5 pg/ml and 40.5 pg/ml
respectively) (p B/0.001). Patients in Rai stage III and
IV also had significantly higher levels of bFGF than
patients in Rai stage 0
/II (median 100.1 pg/ml and
29.3 pg/ml respectively) (p B/0.001). The levels of
both TGF-b1 and endostatin were lower in patients in
Rai stage III and IV (median 28.9 ng/ml and 9.1 ng/ml
respectively) than in patients in Rai stage 0
/II (42.8
ng/ml and 13.1 ng/ml respectively) (p B/0.001 and
p/0.002 respectively). The level of endostatin was
also lower in the group of CLL patients with pro-
gressive disease (median 10.0 ng/ml) as compared to
patients with stable disease (median 20.5 ng/ml) (p/
0.008). In conclusion, the disturbance in the balance
between pro- and anti-angiogenic factors may have
an important influence on the course of CLL.
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Introduction
Angiogenesis is a multi-step process involving en-
dothelial cell proliferation, differentiation, migration
and organisation to form tubules. It has been well
established that angiogenesis is involved in the
expansion and dissemination of primary solid tu-
mors. Many studies have demonstrated an association
between microvessel density and prognosis in differ-
ent cancers.
1 Angiogenesis is regulated by many
substances with pro-angiogenic activity and a num-
ber of inhibitors. Basic fibroblast growth factor
(bFGF) and transforming growth factor beta
(TGFb1) are potent inducers of angiogenesis, enhan-
cing the proliferation of epithelial cells and fibro-
blasts and are involved in the regulation of cellular
replication and synthesis of many components of the
extracellular matrix.
2 Endostatin is a recent discov-
ered, a 20 kDa fragment of the C-terminal, noncolla-
genous domain of collagen XVIII with antiangiogenic
activity. It is able to block mitogen-activated protein
kinase activation in endothelial cells and specifically
inhibits endothelial proliferation.
3
Recent studies indicate that angiogenesis may also
play an important role in the pathogenesis of
hematological malignancies, including lymphoma,
myeloma and leukemia.
46 Evidence of the role of
this process in chronic lymphocytic leukemia (CLL)
originates from the finding that increased vessel
density was observed in the bone marrow of CLL
patients.
7 There are also studies that have revealed
that CLL B cells spontaneously secrete a variety of pro
and anti-angiogenic factors including vascular en-
dothelial growth factor (VEGF), TGFb1, bFGF and
endostatin.
811 The shift in balance between produc-
tion of anti-angiogenic factors and pro-angiogenic
factors is a process that may have significant influ-
ence on disease progression.
The aim of our study was to compare the serum
levels of the pro-angiogenic factors: bFGF and TGFb1
and the anti-angiogenic factor endostatin, between
healthy blood donors and a group of never treated
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167CLL patients. We have also investigated if the levels of
pro- and anti-angiogenic factors correlate with the
stage of the disease.
Patients and methods
Patients
The study involved 80 B-CLL patients and 27 healthy
volunteers. All CLL patients fulfilled the National
Cancer Institute-Sponsored Working Group diagnos-
tic criteria for CLL.
12 There were 48 male patients and
32 female patients with a mean age of 64 years (range
40/78). Forty-four patients had stable disease and 36
had progressive disease (including lymphocytosis
doubling time B/1 year, massive splenomegaly,
bulky adenopathy, recurrent disease-related infec-
tions, weight loss  /10% in a 6-month period,
temperature of 388C related to disease, extreme
fatigue, III and IV Rai stage disease).
13 According to
Rai classification
14 18 patients were in 0 stage, 15 in I,
19 in II, 6 in III and 22 in IV stage of the disease. Fifty-
two patients (Rai 0/II) were included in good
prognosis group and 28 (Rai II/IV) in bad prognosis
group.
15 All patients included in this study were
previously untreated. Characteristics of the patients
are shown in Table 1.
An assessment of history and a physical examina-
tion was performed as initial diagnostic procedure.
The laboratory tests included: complete blood count,
immunoglobulins level, liver and renal function tests,
bone marrow aspiration for morphology and immu-
nophenotyping. Surface marker analysis was per-
formed to confirm B-cell origin and monoclonal
proliferation, including immunoglobulins heavy-
and light-chains, CD5, CD10, CD19, CD20 and CD23.
The controls included 18 men and 9 women, with a
mean age of 52 years (range 40/75).
This project was performed in accordance with the
Helsinki Declaration. Informed consent was obtained
from all patients participating in the study. The local
Ethics Committee approved the project.
Serum sampling and cytokine determination
The serum obtained was stored at  /808C until
assayed for cytokines. The cytokines serum concen-
trations were assayed by specific, commercially
available, enzyme linked assay kits. The kits for
bFGF and TGFb1 were the products of R&D Systems
Inc. (Minneapolis, MN, USA) and the endostatin was
a product of Oncogene Research Products (Boston,
MA, USA). Standards and samples were assayed as
duplicates, and interassay variations were within the
range given by manufacture. Assay sensitivity was 1.0
pg/ml for bFGF, 5.0 ng/ml for TGFb1 and 1.953 ng/
ml for endostatin.
Statistical analysis
Comparisons of values were made with Mann/
Whitney tests. Comparisons were considered signifi-
cant when pB/0.05. The linear correlations between
serum cytokine levels as compared with the lympho-
cyte number were evaluated using the Sperman rank-
sum correlation method.
Results
The serum level of TGFb1 and endostatin were
measurable in all normal individuals and all CLL
patients and bFGF was measurable in 24 out of 27
healthy volunteers and in all CLL patients.
The result of the measurements of TGFb1, bFGF
and endostatin are shown in Table 2.
The serum levels of both bFGF and TGFb1 were
found to be significantly higher in the CLL group
(median 40.5 pg/ml and 38.6 ng/ml, respectively)
when compared to the control group (median 9.4 pg/
ml and 18.9 ng/ml, respectively; pB/0.001). The
levels of endostatin were not significantly different
between the control and the CLL group (median 8.4
ng/ml and 12.3 ng/ml, respectively; p/0.09). In the
group of CLL patients the level of bFGF was
significantly higher in patients with progressive
disease as compared to patients with stable disease
(median 90.5 pg/ml and 40.5 pg/ml, respectively;
p/0.001). Patients in Rai stage III and IV also had
significantly higher levels of bFGF than patients in Rai
stage 0/II (median 100.1 pg/ml and 29.3 pg/ml,
respectively; pB/0.001). The levels of both TGF-b1
and endostatin were lower in patients in Rai stage III
and IV (median 28.9 ng/ml and 9.1 ng/ml, respec-
tively) than in patients in Rai stage 0-II (42.8 ng/ml
Table 1. Patient characteristics
Number of patients 80
Age
Median 64
Range 40/78
Sex (male/female) 48/32
Rai stage
01 8
I1 5
II 19
III 6
IV 22
Stable disease 44
Progressive disease 37
Disease duration (months)
Median 52
Range 3/100
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0.002, respectively). The level of endostatin was also
lower in the group of CLL patients with progressive
disease (median 10.0 ng/ml) as compared to patients
with stable disease (median 20.5 ng/ml; p/0.008).
In the entire group of CLL patients we have found a
negative correlation between the serum level of
TGFb1 and bFGF (p/0.019, R/ /0.26) and the
serum levels of endostatin and bFGF (p/0.0004,
R/0.39). We have also found a positive correlation
between the number of lymphocytes in the periph-
eral blood of CLL patients and the level of bFGF (pB/
0.0001, R/0.48) and endostatin (p/0.0003, R/
0.39).
Discussion
The angiogenic switch in tumor cells is characterised
at a molecular level by an imbalance in the produc-
tion of pro- and anti-angiogenic factors. There is
more and more evidence that B-CLL cells themselves
may be an important source of these factors, but their
exact role in the biology of the disease remains
unclear.
10,16 In order to determine if the levels of pro-
and anti-angiogenic factors are associated with the
course of the disease we compared the levels of
bFGF, TGFb1 and endostatin to the Rai risk stage and
whether a patient has stable or progressive disease.
CLL cells-derived bFGF acts as a paracrine en-
dothelial cells mitogen in angiogenesis. It enhances
the proliferation of a variety of ectoderm- and
mesoderm-derived cells, such as epithelial cells and
fibroblasts.
1 It also acts in an autocrine fashion on
CLL cells behavior such as prolong survival due to
inhibition of apoptosis.
17 Thus, in progressive phase
of CLL, when the lymphocytosis doubling time is
quick and the expansion of lymphoid tissue and
neovascularisation take place, bFGF could play an
important role. Our investigations revealed signifi-
cantly higher serum bFGF levels in CLL patients as
compared to the healthy control group (pB/0.001).
Furthermore we revealed that bFGF concentration is
significantly higher in the serum of patients with
more advanced Rai stage and in those with progres-
sive disease (pB/0.001). We also observed the
positive correlation between the serum level of this
cytokine and the number of lymphocytes in the
peripheral blood. These observations are in agree-
ment with other studies.
17,19 Most of the studies
revealed a positive correlation between the increased
bFGF concentrations and tumor progression or
patient survival. High pre-treatment level of bFGF
has been found an independent predictor of poor
prognosis in non-Hodgkin lymphomas.
19 Our pre-
vious study revealed that serum levels of bFGF and
TGFb1 were significantly higher in progressive CLL
patients than in patients in complete remission.
20
Menzel et al. revealed a high level of bFGF in
lymphocytes of CLL patients, especially those with
high-risk disease.
17 Molica et al. analysed 81 Binet
stage A CLL patients and found that serum levels of
bFGF positively correlated with Rai sub-stages but
failed to demonstrate any correlation between the
bFGF level and disease progression. In contrast to
our results they did not find correlation between
bFGF concentration and peripheral blood lymphocy-
tosis.
18
CLL-B cells were shown to express TGFb1 RNA
and to release bioactive TGFb1 into culture super-
natants.
21 Autocrine secretion of TGFb1 exibits an
antiproliferative effect on CLL-B cells. This effect is
most relevant in B cells cultured in direct contact with
activated CD4 / T cells suggesting an indirect mode
of action.
22 On the other hand TGFb1 is a well known
pro-angiogenic factor.
23 It also has been shown to
potentate the expression of VEGF, the most potent
pro-angiogenic factor in CLL.
24 In our studies we
observed a significantly higher concentration of
TGFb1 in the serum of untreated CLL patients when
compared to the control group (pB/0.001). An
increased TGFb1 level in comparison with healthy
controls has been demonstrated in patients with
renal, colorectal and nasopharyngeal carcinoma.
2527
There was also a correlation between high TGFb1
serum level and advanced tumor stage. In contrast
Table 2. Comparison of serum levels of TGFb1, bFGF and endostatin in the healthy control group and in 80 untreated B-cell
CLL patients
Cytosine Control
(n/27) (A)
All CLL
patients
(n/80) (B)
Stable CLL
(n/43) (C)
Progressive CLL
(n/37) (D)
Rai 0/II
(n/52) (E)
Rai III/IV
(n/28) (F)
Statistically
significant
comparison
TGF-beta (ng/ml) 18.9
(7.0/38.5)
38.6
(13.9/89.0)
13.0
(15.8/89.0)
32.3
(13.9/63.2)
42.8
(13.9/89.0)
28.9
(13.9/42.0)
A vs. B: pB/0.001
C vs. D: pB/0.001
E vs. F: pB/0.001
bFGF
(pg/ml)
9.4
(0/20.1)
40.5
(5.1/230.5)
41.9
(5.1/150.0)
90.5
(10.1/230.5)
29.3
(5.1/150.0)
100.1
(10.1/230.5)
A vs. B: pB/0.001
C vs. D: pB/0.001
E vs. F: pB/0.001
Endostatin
(ng/ml)
8.4
(2.1/21.5)
12.3
(2.9/58.0)
20.5
(6.4/34.0)
10.0
(2.9/58.0)
13.1
(4.4/34.0)
9.1
(2.9/58.0)
A vs. B: p/0.09
C vs. D: p/0.008
E vs. F: p/0.002
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cytokine in patients with advanced CLL stages (pB/
0.001). It is not unexpected because although TGFb1
is a molecule with pro-angiogenic activity it is also
known as an autocrine growth inhibitor of lympho-
cyte proliferation.
28 TGFb1 appears to function in CLL
as a negative regulator of B lymphocytes but loss of
responsiveness to this cytokine accompanied by a
decrease of TGFb1 receptor expression, might pro-
vide a selective advantage to B CLL
lymphocytes.
2931 Moreover this increased TGFb1
production could be responsible for the inhibiting
activity on hematopoietic precursors and bone mar-
row failure seen in advances stages of CLL.
32
In addition to pro-angiogenic growth factors we
evaluated plasma levels of endostatin an endogenous
inhibitor of angiogenesis.
3 However we did not find a
difference between serum levels of this cytokine in
CLL patients and the healthy control group (p/0.09).
Other authors have reported endostatin levels similar
to healthy control in patients with squamous cell
vulvar carcinoma and hepatocellular carcinoma.
33,34
The same observation was made in patients with
rheumatoid arthritis and systemic lupus erythemato-
sus (SLE).
35,36 In contrast Feldman et al. found
significantly elevated serum levels of endostatin in
the serum of patients with clear cell renal carcinoma
and soft tissue sarcoma as compared to healthy
control.
37,38 It is worth noting that in our study, the
serum endostatin levels were significantly lower in
patients with advanced Rai stages or progressive
disease as compared to lower Rai stages and stable
disease (pB/0.001). We also found a positive correla-
tion between the serum concentration of endostatin
and peripheral blood lymphocytosis and a negative
correlation between this cytokine level and bFGF
serum concentration. Similar to our results, a negative
correlation between endostatin and bFGF was also
revealed in patients with SLE.
36 In contrast Bertolini et
al., in series of 36 non-Hodgkin lymphoma patients,
did not find a difference in endostatin level between
patients in complete remission and patients with
progressive disease nor a correlation between endo-
statin levels and event-free survival rate.
39 Feldman et
al. revealed that higher endostatin levels were
associated with an increased risk of tumour recur-
rence after resection of soft tissue sarcoma.
37 They
also found the positive correlation of endostatin and
pro-angiogenic VEGF.
In conclusion, the results of the current study
showed that the levels of anti-angiogenic endostatin
and pro-apoptotic TGFb1 are lower in the serum of
CLL patients in advanced stages or with progressive
disease while the level of pro-angiogenic bFGF is
significantly higher in these groups of patients. The
imbalance between these cytokines may have an
influence on the course of the disease.
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